Through the WB method, we discovered that P-ERK1/2 protein expression within the MAPK pathway was significantly reduced in DLBCL cells when ATOX1 was knocked down, which could be reversed by CuCl2. The gene discussed is MAPK3; the disease is diffuse large B-cell lymphoma.